Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) reported its last quarter results on 11/04/2016. This Company belongs to Medical sector.
In the last trading session, The Company traded 1.68 Million shares. The Stock Market opened sessions at 0.68 and closed at 0.71. There was a stock increase by 5.37 percent.
According to Yahoo Finance, the price target for the company which analysts are aiming is 10. The 1-year price target of the company is 2.85.
Investors expected a price target of -0.13 for this quarter. Zacks Investment Research gave Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) a rating of 2 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.
Considering the performance, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)’s shares have the potential to reach a high EPS of -0.35 per share, and a low EPS of -0.48 per share in the current quarter. All of these Earnings estimates are a consensus recommendation of 5 Analysts. According to them, the median (average) EPS the company could deliver is -0.41/share. While the actual EPS the company reported in the same quarter previous year was -0.18/share.
For the quarter ending 08/09/2016, The Analyst projected that the company could deliver EPS of -0.31 while the company provided its Actual EPS of -0.35 showing a difference of -0.04 Percent between the Estimated and Actual EPS. Hence, the surprise factor was -12.9 percent.
Analysts estimated $-0.38/share for the previous Quarter, where Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) reported Actual EPS of $-0.61/share with the difference of -0.23 percent and a surprise of -60.5 percent.
The 5 analysts offering 12-month price forecasts for Anthera Pharmaceuticals Inc have a median target of 1.00, with a high estimate of 3.00 and a low estimate of 0.90. The median estimate represents a +40.08% increase from the last price of 0.71.
While Looking at Sales Growth (Year/est), the company is currently showing a percentage value of -60.6 percent.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) topped its 52-week high price target of 4.9 on Mar 10, 2016. The company reached a 52-week low at 0.64 on Dec 30, 2016.
The company’s stock currently has 30.5 Million in market capitalization. The volatility rate is 5.20% percent and 9.09% percent each. Price per earning (ttm) stands at 0.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.